Navigation Links
First targeted nanomedicine to enter human clinical studies
Date:4/4/2012

m2 and dose escalation is ongoing. It has been well-tolerated with no new toxicities observed.

"It has been a privilege to be a part of the team that developed this technology at its conception through its clinical translation. The emerging BIND-014 clinical data showing signals of efficacy even at relatively low doses validates the potential for the revolutionary impact of nanomedicines and is a paradigm shift for the treatment of cancer." said Philip W. Kantoff, MD, Chief Clinical Research Officer at DFCI, Professor of Medicine at Harvard Medical School, and study co-author.

"It is wonderful to witness a world-class team of scientists, engineers, physicians, for-profit and non-project organizations converge to develop this potentially revolutionary technology for treatment of cancers. The effectiveness of this team has been remarkable and serves as model for translational research" said Edward J. Benz, Jr. MD, President of DFCI, Richard and Susan Smith Professor of Medicine at Harvard Medical School.

The research and development of the first targeted programmable nanomedicine to show anti-tumor effects in humans represents the culmination of more than a decade of investigation initially carried out in academic labs at BWH and MIT, and supported by funding from the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, The David H. Koch Institute for Integrative Cancer Research at MIT, the Prostate Cancer Foundation, philanthropic gift from David H. Koch, and the Dana-Farber Harvard Cancer Center Prostate Cancer SPORE; and subsequently carried out in the laboratories of BIND Biosciences leading to the development of BIND-014, and supported by funding from the National Cancer Institute, National Institute of Standards and Technology and BIND Biosciences.

BIND Biosciences was launched in 2007 based on technologies that were licensed from BWH and MIT and developed, respectively, in the laborator
'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. First Bedside Gene Test Shows Promise
2. Complications in patients undergoing PCI tend to occur within first 30 days
3. $4.2 million grant helps plan, launch first Alzheimers prevention trials
4. First national guideline for sudden hearing loss published
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. First study of its kind finds no increased risk of heart disease for kidney donors
7. UC San Diego among first in nation to treat brain cancer with novel viral vector
8. First breakdown of public health data for Cleveland neighborhoods
9. Rapid Flu Tests a Good First Step: Study
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Mount Sinai first to use visually guided catheter ablation system to treat AFib patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... cells metastasize? Think of Sparta. , Ancient Greek warriors ... for the demands of battle on distant fields. Cancer ... to a new study revealing previously unknown differences between ... tumor site, and those that travel to other organs. ... metastasize is the primary cause of cancer-related death, understanding ...
(Date:9/21/2014)... 2014 Hundreds of Risperdal lawsuits ... Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard ... next monthly meeting has been scheduled for October ... “Our Firm is representing a number of plaintiffs ... We are pleased with its continued progress,” says ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the ... and GreenGeeks are the best Reseller hosting suppliers in ... hosting supplier. Actually, these companies have outperformed their competitors ... People can get the best web hosting at affordable ... to the manager, reseller hosting is a very popular ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 ... Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a ... and Chinese Fenofibrate (CAS 49562-28-9) industry. The ... Fenofibrate (CAS 49562-28-9) including its classification, application ... and China’s top manufacturers of Fenofibrate (CAS ...
(Date:9/21/2014)... 21, 2014 More than 60 ... added over the past month to a federal ... cardiovascular injuries caused by the dialysis concentrate, Bernstein ... on September 15th shows 2,089 cases filed in ... Court, District of Massachusetts. These claims were filed ...
Breaking Medicine News(10 mins):Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4
... ... sugar and high in antioxidants. Summer is just around the corner so look and feel great ... the healthiest berry on earth! , ... York, NY (PRWEB) April 26, 2010 -- Move over acai, there’s a new berry in town ...
... degrees, for men with advanced disease, studies found, , ... this week of a therapeutic prostate cancer vaccine by ... milestone against the disease and cancer in general, experts ... survival in men with advanced prostate cancer, and it ...
... , ... at the recent 2010 DTC National Conference in Washington, D.C., agreed 2-1 that they would ... , ... Park, NJ (PRWEB) April 27, 2010 -- DTC Perspectives, Inc ., the leading conference, ...
... ... Exclusively at Target, with four all-natural treatment collections for all hair types and ethnicities. ... (PRWEB) April ... Care, which debuted exclusively in 233 Target stores on March 28, 2010. An ...
... ... their own custom branded mobile application to iPhone, iPad, and Android devices without having to ... ... its platform that allows businesses to build and deploy their own mobile application, ...
... ... to take place on May 6, 2010. Two years in the planning and development, ... center offers nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott ...
Cached Medicine News:Health News:Supercharge Summer with Superfood-infused Cookies! 2Health News:Supercharge Summer with Superfood-infused Cookies! 3Health News:Prostate Cancer Vaccine May Get FDA Approval 2Health News:Prostate Cancer Vaccine May Get FDA Approval 3Health News:Top DTC Marketers Choose Obama Over Romney and Palin 2Health News:Top DTC Marketers Choose Obama Over Romney and Palin 3Health News:Sundial Creations Announces the Debut of SheaMoisture Organic Hair Care Exclusively at Target 2Health News:Snowflake Mobile™ Launches Platform for Creating and Deploying Mobile Apps 2Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
(Date:9/19/2014)... Kiromic, LLC, a Lubbock bio-pharmaceutical company, ... former chancellor of Texas Tech University, to its board as ... after raising $1.2 billion for the university. "Kiromic ... most successful chancellor in the history of Texas Tech University, ... but also as our new vice chairman of the board. ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014  For ... cloud-based drug design and development, partnering is an ... mission is to design new drugs and identify ... 2 partners to further their development. The company ... investments. To support this business model, Cloud Pharmaceuticals ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Data in Pediatric Patients,Presented at the American ... N.J., Nov. 11 Daiichi Sankyo,Inc. (DSI), ... study supporting,the use of colesevelam HCl in ... presented for the first time at the,American ...
... 3.5 Fold Higher ... Compared to Standard Chemotherapy, SEATTLE, Nov. 11 ... it achieved the primary,efficacy endpoint of its phase III EXTEND ... non-Hodgkin,s,lymphoma (NHL) based on a preliminary intent to treat efficacy ...
Cached Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: